Johana Patricia Mogollon Díaz, Linda Yurani Lizcano Toloza, Angie Yarlady Serrano García, Camilo Andrés Alquichire Luna, Diego Fernando García Bohorquez, María Fernanda Chaparro Durán, María Valentina Cáceres Valero
INTRODUCTION: Neuroleptic malignant syndrome (NMS) is uncommon, with an incidence of 0.01%-3.23%, and is associated with the use of drugs that intervene with dopamine, causing hyperthermia, muscular rigidity, confusion, autonomic instability and death. CASE REPORT: A 35-year-old man with a history of catatonia, refractory epilepsy and functional impairment, required frequent changes in his anticonvulsant and antipsychotic treatment, due to adverse effects. During 2019, in the month of July, clozapine was changed to amisulpride, in September he developed fever, muscle stiffness, stupor, diaphoresis and tachypnea over a two-week period; paraclinical tests showed elevated creatine phosphokinase (CPK) and leukocytosis, so NMS was considered...
2023: Revista Colombiana de psiquiatría (English ed.)